Skip to main content

Table 2 Recurrence-free survival prognostic factors

From: Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation

Variable

Recurrence-free survival

Univariate

Multivariate

HR (95% CI)

P

HR (95% CI)

P

Age

1.24 (0.98, 1.56)

0.068

1.19 (0.94, 1.51)

0.142

Male

0.94 (0.64, 1.36)

0.732

  

Tumor number

1.47 (1.13, 1.91)

< 0.001

1.32 (1.00, 1.73)

0.048

Tumor size

1.32 (1.18, 1.49)

< 0.001

1.26 (1.11, 1.43)

< 0.001

Risk area

1.20 (0.94, 1.53)

0.138

  

AFP ≥200 ng/mL

1.25 (0.99, 1.57)

0.067

1.25 (0.98, 1.58)

0.067

Pre-TACE

1.23 (0.96, 1.58)

0.097

1.07 (0.82, 1.40)

0.606

PLT < 100 × 109/L

1.28 (1.02, 1.60)

0.032

1.18 (0.93, 1.84)

0.169

RBC < 4.3 × 109/L

1.00 (0.79, 1.26)

0.975

  

WBC < 4.0 × 109/L

1.20 (0.93, 1.56)

0.161

  

ALB < 35 g/L

1.48 (1.07, 2.06)

0.019

1.30 (0.92, 1.84)

0.133

ALT < 50 U/L

1.00 (0.78, 1.28)

0.990

  

AST < 40 U/L

1.07 (0.85, 1.35)

0.578

  

TBIL > 17.1 μmol/L

1.01 (0.96, 1.07)

0.695

  

PT > 16.5 s

0.80 (0.40, 1.63)

0.545

  

Cirrhosis

1.12 (0.88, 1.57)

0.263

  
  1. Abbreviations: AFP alpha-fetoprotein, TACE transcatheter arterial chemoembolization, PLT platelet, RBC red blood cell, WBC white blood cell, ALB albumin, ALT alanine aminotransferase, AST aspartate aminotransferase, TBIL total bilirubin, PT prothrombin time
  2. Variables with P value < 0.10 at univariate analysis were retained for multivariate analysis
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us